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Summary
Congenital dyserythropoietic anemias (CDA) are genetic
disorders characterized by anemia and ineffective
erythropoiesis. Three main types of CDA have been
distinguished: CDA I and CDA III, whose loci have been
already mapped, and CDA II (MIM 224100), the most
frequent among CDAs, which is transmitted as an
autosomal recessive trait and is known also as
“HEMPAS” (hereditary erythroblast multinuclearity
with positive acidified serum). We have recruited a panel
of well-characterized CDA II families and have used
them to search for the CDA II gene by linkage analysis.
After the exclusion of three candidate genes, we ob-
tained conclusive evidence for linkage of CDA II to
microsatellite markers on the long arm of chromosome
20 (20q11.2). A maximum two-point LOD score of 5.4
at a recombination fraction of .00 was obtained with
marker D20S863. Strong evidence of allelic association
with the disease was detected with the same marker.
Some recombinational events established a maximum
candidate interval of ∼5 cM.
Introduction
Congenital dyserythropoietic anemias (CDA) are genetic
disorders characterized by anemia and ineffective eryth-
ropoiesis. Three main types of CDA have been distin-
guished: CDA I, recently mapped to 15q15.1-15.3 (Ta-
mary et al. 1996); CDA III, mapped ∼20 cM telomeric
to the CDA I locus (Lind et al. 1995); and CDA II (MIM
224100), the most frequent among CDAs, which is
transmitted as an autosomal recessive trait and is known
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also as “HEMPAS” (hereditary erythroblast multinu-
clearity with positive acidified serum) (Crookston et al.
1969). It is characterized by normocytic anemia, variable
jaundice, and hepatosplenomegaly. Gallbladder disease
and hemochromatosis are frequent complications (Io-
lascon et al. 1996). Bone-marrow histology reveals bi-
and multinucleated (10%–40%) erythroblasts with kar-
yorrehexis and additional abnormalities detectable by
electron microscopy (Wong et al. 1972). Knowledge
about CDA II has undergone two fundamental steps.
The first was the discovery of the red blood cell (RBC)
membrane-protein abnormality, hypothesized on the ba-
sis of increased agglutinability and Ham test positivity.
SDS-PAGE of RBC membrane proteins shows a nar-
rower aspect and a faster migration of band 3 (anion-
exchange transporter) (Anselstetter et al. 1977; Alloisio
et al. 1996). CDA I differs from CDA II because it does
not show any band 3 biochemical alteration, whereas
CDA III is characterized by different bone-marrow find-
ings and is inherited in a dominant way.
The second step was the discovery of the protein-gly-
cosylation defect. Carbohydrate-structure analysis of
both membrane glycoproteins and soluble glycoproteins,
as well as biochemical data, indicate that CDA II is as-
sociated with defects in the biosynthesis of complex N-
linked oligosaccharides (Fukuda et al. 1987, 1990; Fu-
kuda 1990) . The altered distribution of membrane gly-
coproteins may result in morphologically visible abnor-
malities and could interfere with functions required for
intracellular transport and compartmentalization, cell
division, and differentiation. These structural findings
could be partially explained by the deficiency of some
enzymes, such as N-acetylglucosaminyltransferase II
(GnT-II) or alpha-mannosidase II (alpha-Man II) (Fu-
kuda et al. 1987, 1990; Fukuda 1990), a deficiency that
already has been demonstrated in vitro in several CDA
II patients. Genes encoding for these enzymes have been
cloned (Moremen and Robbins 1991; Misago et al.
1995; Tan et al. 1995), but linkage analysis recently has
excluded them as candidate genes (Iolascon et al., in
press).
To localize the gene for CDA II, a linkage study using
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Figure 1 Schematic representation of CDA II pedigrees included in present study
maps of microsatellites was performed. To facilitate the
genome search, the screening was initially limited to the
affected sibs of a subset of six families. One of these
families was the result of a mating between first cousins;
thus allele homozygosity was sought in the affected
child. In the sibs of the remaining five families, identity
by descent was expected. Alleles of these loci were then
typed in the corresponding parents and members of the
family.
Families and Methods
Families
Twelve Italian families and one French family, all un-
related, were ascertained through pediatric hematology
centers and were included in the study. Six of them were
each characterized by at least two affected individuals,
whereas the remaining six were each characterized by
one affected sib and one or more normal sibs. Finally,
a consanguineous pedigree, the result of a mating be-
tween first cousins, was also selected and included. The
pedigrees of the families enrolled in the study are shown
in figure 1; clinical details of the patients have been de-
scribed elsewhere (Alloisio et al. 1996). The age at onset
was 1–14 years. All individuals included in this study
were accurately investigated at the clinical and labora-
tory levels (blood-cell count and RBC membrane-protein
PAGE). Diagnosis was based on the following criteria:
anemia of variable degree, jaundice, and mild hepato-
splenomegaly. Bone-marrow observation demonstrated
the presence of the typical morphological abnormalities.
SDS-PAGE (Wong et al. 1972) showed, in all affected
cases, a band 3 with a narrower aspect and a faster
migration. The presence of 74-kD and 58-kD proteins
was established by means of immunoblotting using poly-
clonal rabbit antibodies against rat GRP78 (affinity bio-
reagents; Neshanic Station) and rabbit antibodies
against human calreticulin (Alloisio et al. 1996). Pe-
ripheral blood was obtained from all subjects, and DNA
was isolated from blood leukocytes, according to stan-
dard methods.
Search Strategy and Microsatellite Analysis
For the genomewide search, the ABI PRISM linkage
mapping set (Perkin-Elmer) was used. It is characterized
by 1375 markers that define a 10-cM-resolution human
index map (Gyapay et al. 1994). PCR reactions using
fluorescently labeled primers were run under the con-
ditions suggested by the supplier. An aliquot of PCR
reaction was run in an ABI PRISM 373 or an 377 DNA
sequencer, and results were processed by GENESCAN
software. Allele assignment was performed by use of
Genotyper software. To saturate the chromosome
20–positive region, additional pairs of fluorescently la-
beled primers were specifically synthesized for the fol-
lowing markers: D20S912, D20S200, D20S890,
D20S884, D20S863, and D20S908 (Dib et al. 1996).
All living individuals of each family were genotyped and
thus contributed to the linkage calculations.
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Table 1
Pairwise LOD Scores between CDAII and Chromosome 20 Markers
MARKER
LOD SCORE AT RECOMBINATION FRACTION OF
Zmax vmax.0 .01 .05 .10 .20 .30 .40
D20S912  2.01 2.24 1.97 1.22 .57 .16 2.27 .037
D20S200  .47 1.92 2.10 1.62 .89 .26 2.11 .090
D20S890  1.72 .58 1.17 1.15 .69 .21 1.26 .140
D20S195 4.50 4.39 3.92 3.34 2.18 1.14 .34 4.50 .000
D20S863 5.41 5.25 4.65 3.91 2.50 1.28 .37 5.41 .000
D20S884  4.74 4.76 4.22 2.86 1.53 .45 4.89 .026
D20S908  .36 1.86 2.04 1.58 .88 .26 2.05 .090
D20S107  1.06 .69 1.14 1.08 .65 .20 1.20 .130
Figure 2 Linkage map of microsatellite markers from chromosome 20q11.2. Genetic distances are indicated (in cM). The position of
contig WC20.4 (Whitehead Institute/MIT Center for Genome Research) is also reported.
Linkage Analysis
Statistical analysis was performed on the basis of an
autosomal disease with complete penetrance. The dis-
ease-gene frequency was set to .012, and all marker al-
leles were considered to be equally frequent. Two-point
linkage analysis was performed by use of the MLINK
program, version 5.1, from the LINKAGE computer
package (Ott 1992). Loops of consanguinity were ac-
commodated as suggested by Ott (1992). Values for
maximum LOD score (Zmax) were calculated with the
ILINK program, from the same computer package. The
∼95% confidence limits for the maximum recombina-
tion fraction (vmax) at the Zmax were calculated by the 1
 LOD–down method (Ott 1992). Alleles were down-
coded, without loss of informativity, to reduce comput-
ing time. The HOMOG program was used to test for
nonallelic heterogeneity, by use of pairwise LOD scores
between D20S863 and the disease locus. The statistical
significance of linkage disequilibrium with the disease
was tested by utilization of the x2 test of homogeneity
for each marker and then was standardized to obtain
the delta coefficient, whose range is 0–1, to measure
the association. The delta coefficient is defined as
, where a and b(ad bc)/ [(a b)(c d)(a c)(b d)]
are the frequencies of allele 1 in affected and unaffected
chromosomes, respectively, and c and d are the fre-
quencies of allele 2 in the same sets of chromosomes.
Results
After analysis of data from 145 markers, representing
∼50% of the human genome, evidence for linkage was
obtained with markers D20S195 and D20S107, whereas
negative results were obtained for the remaining mark-
ers, including those of chromosome 15, where both the
CDA I locus and the CDA III locus have been mapped.
Six additional markers from the region—D20S912,
D20S200, D20S890, D20S884, D20S863, and
D20S908—were then typed, both in all individuals of
the six families used for the genomewide search and in
an additional six families each containing a single af-
fected individual and one or two unaffected siblings.
Finally, a family characterized by three affected and three
healthy children was included too. The order and the
distances of the aforementioned markers, as deduced
from published maps (Dib et al. 1996), are cen–
D20S912– –D20S200– –D20S890–D20S195–5 cM 3 cM
D20S863–D20S884– –D20S908– –D20S107–3 cM 1 cM
tel. Pairwise LOD scores for the eight markers are shown
in table 1, and the linkage map for these markers is
shown in figure 2.
The highest LOD score ( at ) wasZ  5.41 v  .00max
obtained with D20S863 , but no recombinants were de-
tected also with D20S195 ( at ). Pos-Z  4.5 v  .00max
itive results were also obtained with the remaining six
markers, at v 1 0. The HOMOG program detected no
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Figure 3 Examples of some recombinational events that help in refining the CDA II gene location (families CDAGE and CDACE). A
consanguineous family (with mating between two first cousins), CDABE, is also reported to confirm, by homozygosity, the region defined by
the recombinants. The order of markers is D20S912-D20S200-D20S890-D20S195-D20S863-D20S884-D20S908-D29S107.
evidence in support of genetic heterogeneity ( 2x 
; ). Several recombinations were detected24.928 a  1
that help in definition of the limits of the CDA II gene
location. The centromeric limit is clearly defined by
marker D20S890, which shows a recombinational event
in family CDAGE (fig. 3), whereas additional recom-
binants have been detected in the sample with markers
located more centromeric (D20S200 and D20S912). A
recombinant in family CDACE indicates that the CDAII
gene is located proximal to D20S908 (fig. 3). These lim-
its are confirmed by the consanguineous family, in which
allele homozygosity was expected in the affected child.
As is shown in figure 3, he is homozygous for the alleles
of D20S863, D20S195, and of D20S884, which are lo-
cated within the region previously defined. Haplotype
analysis based on the use of these three markers revealed
in this subject the presence of a rare haplotype (141-
227-137), further confirming the role of homozygosity
in the definition of the limits for the CDA II locus in
this family. The region spanning D20S890–D20S908 is
∼5 cM. Since these two markers are located on chro-
mosome 20q11.2, we propose this region as the location
for the CDA II gene.
Further evidence for the location of the CDA II gene
in this interval was obtained by linkage-disequilibrium
analysis performed by use of one randomly affected in-
dividual for each unrelated family. As already men-
tioned, no recombinants for loci D20S195 and D20S863
were detected in the families that we studied. This last
locus also exhibited strong allelic association with the
disease ( ; ). Allele 2 was present in2x  12.74 P ! .0001
20/26 (.769) of the inferred disease chromosomes, com-
pared with 5/23 (.217) of the nondisease chromosomes,
giving a disequilibrium coefficient of . A dif-d  .552
ferent, but not statistically significant, allele distribution
was also observed with D20S195 ( ; ),2x  2.07 P  .15
with allele 6 being present in 4/26 (.153) disease chro-
mosomes and never in normal chromosomes ( )d  .288
and with D20S908 ( ; ), with allele 52x  1.05 P  .22
being present in 11/26 (.423) affected chromosomes and
in 5/23 (.217) nondisease chromosomes ( ). Thed  .22
strong association of the disease with D20S863 allele 2
suggests the presence of a major mutation and, most
likely, a founder effect. This finding is in agreement with
the origin of our sample, which comes mainly from
southern Italy (i.e., Campania and the areas surrounding
it).
Discussion
Very recently we have excluded, by linkage analysis,
GnT-II, alpha-Man II, and alpha-mannosidase X as can-
didates for the disease (Iolascon et al., in press). In the
present paper, we report the identification of the locus
for CDA II, the most common form of CDA, after the
exclusion of ∼50% of the human genome by a genome-
wide search performed by use of panels of fluorescently
labeled microsatellites. This finding is an important step
toward the cloning of the gene itself. The candidate re-
gion here defined is quite small, ∼5 cM, but additional
analysis with new markers in an expanded set of families
should lead to a further refinement of the CDA II lo-
cation. Of the several genes mapped within this region,
none has any apparent relationship with the disease. In
any case, the region marked by D20S884, D20S195, and
D20S908 is already contained in an available YAC con-
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tig (WC20.4; Whitehead Institute/MIT Center for Ge-
nome Research). As soon as it is extended to markers
D20S863 and D20S890, it will be useful for cloning the
CDA II gene. cDNA selection and exon-trapping tech-
niques will be useful for isolation of expressed sequences
and, together with already cloned ESTs, for construction
of a transcriptional map of the region. The identification
of the CDA II gene will lead to the understanding of the
molecular basis of one of the few inborn errors of me-
tabolism that involve the biosynthesis of a glycoprotein.
Finally, our results clearly demonstrate that the clinical
and laboratory differences detectable between CDA II
and the two other forms of CDA (CDA I and CDA III)
are certainly due to a different genetic background.
Acknowledgments
We thank the families and the physicians associated with
Associazione Italiana Ematologia Oncologia Pediatrica who
collaborated in this work. This work was supported in part
by the Ministero Italiano della Sanita´ (support to P.G.) and
the Associazione Italiana Ricerca Cancro (support to A.I.).
References
Alloisio N, Texier P, Denoroy L, Berger C, Miraglia del Giudice
E, Perrotta S, Iolascon A, et al (1996) The cisternae deco-
rating the red blood cell membrane in congenital dys-
erythropoietic anemia (type II) originate from the endo-
plasmic reticulum. Blood 87:4433–4438
Anselstetter V, Horstmann HJ, Heimpel H (1977) Congenital
dyserythropoietic anemia type I and II: aberrant pattern of
erythrocyte membrane proteins in CDA II, as revealed by
two-dimensional polyacrylamide gel electrophoresis. Br J
Haematol 35:209–217
Crookston JH, Crookston MC, Burnie KL, Fracombe WH,
Dacie JV, Davis H, Lewis SM (1969) Hereditary erythro-
blastic multinuclearity associated with a positive acidified-
serum test: a typical congenital dyserythropoietic anemia.
Br J Haematol 17:11–23
Dib C, Faure´ S, Fizames C, Samson D, Drout N, Vignal P,
Millasseau P, et al (1996) A comprehensive genetic map of
the human genome based on 5264 microsatellites. Nature
380:152–154
Fukuda MN (1990) HEMPAS disease: genetic defect of gly-
cosilation. Glycobiology 1:9–15
Fukuda MN, Dell A, Scartezzini P (1987) Primary defect con-
genital dyserythropoietic anemia type II: failure in glyco-
sylation of erythrocyte lactosaminoglycan proteins caused
by lowered N acteylglucosaminyltransferase II. J Biol Chem
262:7195–7199
Fukuda MN, Masri KA, Dell A, Luzzatto L, Moremen KW
(1990) Incomplete synthesis of N-glycans in congenital dys-
erythropoietic anemia type II (HEMPAS) caused by a gene
defect encoding a mannosidase II. Proc Natl Acad Sci USA
87:7443-7448
Gyapay G, Morissette J, Vignal A, Dib C, Fizames C, Millas-
seau P, Samson D, et al (1994) The 1993–1994 Ge´ne´thon
human genetic linkage map. Nat Genet 7:246–339
Iolascon A, D’Agostaro G, Perrotta S, Izzo P, Tavano R, Mir-
aglia del Giudice E (1996) Congenital dyserythropoietic ane-
mia type III: molecular basis and clinical aspects. Haema-
tologica 81:543–559
Iolascon A, Miraglia del Giudice E, Perrotta S, Granatiero M,
Zelante L, Gasparini P. Exclusion of three candidate genes
as determinants of congenital dyserythropoietic anemia type
II. Blood (in press)
Lind L, Sandstrom H, Wahlin A, Eriksson M, Nilsson-Sojka
B, Sikstrom C, Holmgren G, et al (1995) Localization of
the gene for congenital dyserythropoietic anemia type III,
CDAN3, to chromosome 15q21-25. Hum Mol Genet 4:
109–112
Misago M, Liao YF, Kudo S, Eto S, Mattei MG, Moremen
KW, Fukuda MN (1995) Molecular cloning and expression
of cDNAs encoding human a-mannosidase II and a previ-
ously unrecognized a-mannosidase IIx isozyme. Proc Natl
Acad Sci USA 92:11766–11770
Moremen KW, Robbins PW (1991) Isolation, characterization
and expression of cDNAs encoding murine a-mannosidase
II, a Golgi enzyme that controls conversion of high mannose
to complex N-glycans. J Cell Biol 115:1521–1534
Ott J (1992) Analysis of human linkage, 2d ed. John Hopkins
University Press, Baltimore
Tamary H, Shalmon L, Shalev H, Halil A, Shaft D, Zoldan
M, Resnitzky P, et al (1996) Localization of the gene for
congenital dyserythropoietic anemia type I to chromosome
15q15.1-15.3. Blood 88 Suppl 1:144a
Tan J, D’Agostaro G, Bendiak B, Reck F, Sarkar M, Squire
JA, Leong P, et al (1995) The human UDP-N-acetylglucosa-
mine: a-6-D-mannoside-b-1,2-N-acetylglucosaminyltrans-
ferase gene (MGAT2): cloning of genomic DNA, localization
to chromosome 14q21, expression in insect cells and puri-
fication of the recombinant protein. Eur J Biochem 231:
317–328
Wong KY, Hug G, Lampkin BC (1972) Congenital dys-
erythropoietic anemia type II: ultrastructural and radioau-
tographic studies of blood and bone marrow. Blood 39:
23–30
